alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**UN PUBLISHED** 
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

**No. 16**  **- 6106** 

UNITED STATES OF AMERICA , Plaintiff

- Appellee ,
v. ANTHONY VONN HARRIS, a/k/a Anthony Vonne Harris , Defendant

- Appellant
.

Appeal from the United States District Court for the Middle District of North Carolina , at Greensboro
. Thomas D. Schroeder , District Judge. ( 1:10

- cr - 00289

- TDS

- 1; 1:13

- cv - 00232

- TDS

- JEP )

Submitted : June 23, 2016 Decided: June 28, 2016

Before MOTZ, KING, and WYNN , Circuit Judges.

Dismissed by un published per curiam opinion
. Anthony Vonn Harris, Appellant Pro Se. Clifton Thomas Barrett, Harry L. Hobgood, Angela Hewlett Miller, Assistant United States Attorneys, Greensboro, North Carolina, for Appellee.
Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM: Anthony Vonn Harris seeks to appeal the district court’s order accepting the recommendation of the magistrate judge and denying relief on his 28 U.S.C. § 2255 (2012) m otion. The order is not appealable unless a circuit justice or judge issues a certificate of appealability. 28 U.S.C. § 2253(c)(1) (B) (2012)
. A certificate of appealability will not issue absent “a substantial showing of the denial of a constitutional r ight.” 28 U.S.C. § 2253(c)(2) (2012)
. When the district court denies relief on the merits, a prisoner satisfies this standard by demonstrating that reasonable jurists would find that the district court’s assessment of the constitutional claims is debatab le or wrong. Slack v. McDaniel , 529 U.S. 473, 484 (2000); see Miller

- El v. Cockrell , 537 U.S. 322, 336

- 38 (2003). When the district court denies relief on procedural grounds, the prisoner must demonstrate both that the dispositive procedural ruling is de batable, and that the motion states a debatable claim of the denial of a constitutional right. Slack , 529 U.S. at 484

- 85. We have independently reviewed the record and conclude that Harris has not made the requisite showing. * Accordingly, we deny

* Specifically, the district court’s dispositive conclusion

— that our decision in United States v. Mungro , 754 F.3d 267 (4th Cir. 2014), foreclosed Harris’ argument that the Supreme (Continued)3 a cer tificate of appealability and dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before th is court and argument would not aid the decisional process.

DISMISSED

Court’s holding in Johnson v. United States , 135 S. Ct. 2551 (2015), invalidated his armed career criminal designation

— is not debatable.
§ 186.1275 Dextrans. ( a ) Dextrans (CAS Reg. No. 9004-54-0) are high molecular weight polysaccharides produced by bacterial fermentation of sucrose. Commercially available dextrans are synthesized from sucrose by *Leuconostoc mesenteroides* strain NRRL B-512(F). Partial depolymerization and purification of the fermented mixture shall produce a product that is free of viable microorganisms.
( b ) The ingredient is used or intended for use as a constituent of food-contact surfaces.
( c ) The ingredient is used at levels not to exceed good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[43 FR 29288, July 7, 1978, as amended at 48 FR 48457, Oct. 19, 1983]
1

Palma, Elizabeth

From: Nancy Kruger <nkruger@4cleanair.org>

Sent: Wednesday, December 02, 2015 9:38 PM

To: Palma, Elizabeth

Cc: Jones, Rhea; Mathias, Scott

Subject: Invitation: NACAA call on exceptional events

Dear Beth, 

NACAA invites you and your EPA colleagues to join us on a conference call on Friday, December 11, 

2015, to respond to our members' clarifying questions on EPA's proposed exceptional events rule and 

draft wildfire guidance. The call will begin at 1:30 PM Eastern and we expect this Q&A portion to run 

about 30 minutes after which we'll continue with a NACAA-only discussion. The call-in number and 

access code are 

We will ask our members to provide questions in advance and will forward those to you on 

Wednesday, December 9. We'll start with those questions and then open it up for additional 

questions as time allows. I don't think we'll need an EPA overview of the proposal and draft 

guidance; hopefully folks have already begun digging into these documents. 

We'll take roll at the beginning of the call and I'll provide you with a list of participating NACAA state 

and local air agencies following the call. 

Please confirm your participation and also let me know if you have any questions. 

Thanks, 

-Nancy 

_________________________________ 

Nancy Kruger 

Deputy Director 

National Association of Clean Air Agencies 

444 North Capitol Street, NW 

Suite 307 

Washington, DC 20001 

 
1

Palma, Elizabeth

From: Palma, Elizabeth

Sent: Wednesday, December 16, 2015 10:31 AM

To: Palma, Elizabeth

Subject: FW: Invitation: NACAA call on exceptional events - List of Attendees (For Docket)

EPA Participants on the December 11, 2015 Call

Beth Palma, USEPA/OAQPS

Mark Evangelista, USEPA/OAQPS

Justin Spenillo, USEPA/Region 10

Michael Flagg, USEPA/Region 9

From: Nancy Kruger [mailto:nkruger@4cleanair.org]  

Sent: Wednesday, December 16, 2015 8:27 AM

To: Palma, Elizabeth <Palma.Elizabeth@epa.gov>

Subject: Re: Invitation: NACAA call on exceptional events ‐ List of Attendees

Hi Beth, 

Here's the list from roll call: 

Rhode Island 

Connecticut 

Massachusetts 

Maryland 

Pennsylvania 

West Virginia 

Alabama 

Tennessee 

Georgia 

South Carolina 

Mississippi 

Kentucky 

Wisconsin 

Minnesota 

Illinois 

Michigan 

Oklahoma 

Arkansas 

New Mexico 

Iowa 

Missouri 

Kansas 

Utah 

Wyoming 

Colorado 

Nevada 

California 
2

Washington 

Idaho 

Alaska 

Knox Co., TN 

Vandenburg Co., IN 

Harris Co., TX 

Ventura, CA 

Sacramento, CA 

San Diego, CA 

Los Angeles, CA 

Washoe Co., NV 

Seattle, WA 

Yakima, WA 

Spokane, WA 

NACAA 

SESARM 

CenSARA 

WESTAR 

Thanks again, 

-Nancy 

____________________________ 

Nancy Kruger 

Deputy Director 

National Association of Clean Air Agencies 

444 North Capitol Street, NW 

Suite 307 

Washington, DC 20001
-80 -79 -78 -77 -76 -75 -74

 39

 40

 41

 42

★

▲

▲

▲

▲

★

▲

▲

▲

▲

 500

 1000

 1500

 500

18 12 06 00

08/07

NOAA HYSPLIT MODEL

 Backward trajectory ending at 2300 UTC 07 Aug 07

 EDAS Meteorological Data

Source

★ at 39.41 N 76.30 W Meters AGL
#### § 522.1920 Prochlorperazine and isopropamide.

(a) *Specifications.* Each milliliter of solution contains prochlorperazine edisylate equivalent to 4 milligrams (mg) prochlorperazine and isopropamide iodide equivalent to 0.28 mg of isopropamide.

(b) *Sponsor.* See No. 054771 in [§ 510.600(c) of this chapter](/on/2024-09-17/title-21/section-510.600#p-510.600(c)).

(c) *Conditions of use* —

(1) *Amount.*

(i) Dosage is administered by subcutaneous injection twice daily as follows:

| Weight of animal in pounds | Dosage in milliliters |
| --- | --- |
| Up to 4 | 0.25 |
| 5 to 14 | 0.5-1 |
| 15 to 30 | 2-3 |
| 30 to 45 | 3-4 |
| 45 to 60 | 4-5 |
| Over 60 | 6 |

(ii) Following the last injection, administer prochlorperazine and isopropamide sustained release capsules as indicated.

(2) *Indications for use.* For use in dogs and cats in which gastrointestinal disturbances are associated with emotional stress.

(3) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[[79 FR 16194](https://www.federalregister.gov/citation/79-FR-16194), Mar. 25, 2014]
Materials Not Included in

Airworthiness Directive (AD) Docket

Docket Number: FAA- 2011-0572

Directorate Identifier: 2011NM009AD

ACB GV 30 --- 12/6/10

ACB G500 10 ---12/6/10

ACB G550 10 --- 12/6/10

Name/Description of Item(s) Not Included in FDMS Docket and Maintained in the 

Supplemental AD Docket

MAY BE VIEWED AT: Federal Aviation Administration

Transport Airplane Directorate

Rules Docket

1601 Lind Ave. SW.,

Renton, WA 98057

425.227.1221

DURING THE HOURS OF: 9 a.m. and 3 p.m., Monday through Friday,

except Federal holidays.

Form Date: 03/05/2008
<PAGE>
                                                                    Exhibit 99.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Front Range Capital Corporation (the
"Company") on Form 10-Q for the period ending June 30, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I , Robert
L. Beauprez, Chief Executive Officer and President of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

         (1) The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.

/s/  Robert L. Beauprez


Robert L. Beauprez
Chairman of the Board and President
August 12, 2002
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AT SEPTEMBER 30, 2000, AND THE STATEMENTS OF OPERATIONS FOR THE NINE
MONTHS ENDED SEPTEMBER 30, 2000.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                      30,636,124
<SECURITIES>                                         0
<RECEIVABLES>                                  101,341
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            32,146,914
<PP&E>                                       7,411,061
<DEPRECIATION>                             (1,710,083)
<TOTAL-ASSETS>                              41,653,295
<CURRENT-LIABILITIES>                        1,810,302
<BONDS>                                     21,421,991
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        19,520
<OTHER-SE>                                  18,401,482
<TOTAL-LIABILITY-AND-EQUITY>                41,653,295
<SALES>                                      4,596,527
<TOTAL-REVENUES>                             4,596,527
<CGS>                                                0
<TOTAL-COSTS>                               15,025,572
<OTHER-EXPENSES>                           (2,161,876)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           2,466,061
<INCOME-PRETAX>                           (10,733,230)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                       (10,733,230)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                              7,287,838
<CHANGES>                                            0
<NET-INCOME>                               (3,445,392)
<EPS-BASIC>                                      (.18)
<EPS-DILUTED>                                    (.18)<F1>
<FN>
<F1>INCLUDES $2,214,653 IN INTEREST INCOME.
</FN>


</TABLE>
§ 520.998 Fluralaner. ( a ) *Specifications.* ( 1 ) Each chewable tablet contains 112.5, 250, 500, 1,000, or 1,400 milligrams (mg) fluralaner.
( 2 ) Each chewable tablet contains 45, 100, 200, 400, or 560 mg fluralaner.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer orally as a single dose with food: ( i ) *Chewable tablets described in paragraph (a)(1) of this section.* Administer every 12 weeks, an appropriate combination of tablets to provide a minimum dose of 11.4 mg per pound (lb) (25 mg per kilogram (kg)) body weight. May be administered every 8 weeks in case of potential exposure to *Amblyomma americanum* ticks.
( ii ) *Chewable tablets described in paragraph (a)(2) of this section.* Administer monthly, an appropriate combination of tablets to provide a minimum dose of 4.5 mg/lb (10 mg/kg) body weight.
( 2 ) *Indications for use* — ( i ) *Chewable tablets described in paragraph (a)(1) of this section.* Kills adult fleas; for the treatment and prevention of flea infestations (*Ctenocephalides felis*), and the treatment and control of tick infestations (*Ixodes scapularis* (black-legged tick), *Dermacentor variabilis* (American dog tick), *Rhipicephalus sanguineus* (brown dog tick), and *Haemaphysalis longicornis* (Asian longhorned tick)) for 12 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 lbs or greater; and for the treatment and control of *Amblyomma americanum* (lone star tick) infestations for 8 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 lbs or greater.
( ii ) *Chewable tablets described in paragraph (a)(2) of this section.* Kills adult fleas; for the treatment and prevention of flea infestations (*C. felis*), and the treatment and control of tick infestations [*I. scapularis* (black-legged tick)*, D. variabilis* (American dog tick)*,* and *R. sanguineus* (brown dog tick)] for 1 month in dogs and puppies 8 weeks of age and older, and weighing 4.4 lbs or greater; and for the treatment and control of *A. americanum* (lone star tick) infestations for 1 month in dogs and puppies 6 months of age and older, and weighing 4.4 lbs or greater.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[86 FR 14818, Mar. 19, 2021, as amended at 88 FR 27698, May 3, 2023]
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Pages 9004-9005]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4105]


-----------------------------------------------------------------------

OVERSEAS PRIVATE INVESTMENT CORPORATION


Sunshine Act; Notice of Meeting

TIME AND DATE:  March 17, 2010, 2 p.m.

PLACE:  Offices of the Corporation, Twelfth Floor Board Room, 1100 New 
York Avenue, NW., Washington, DC.

STATUS: Hearing OPEN to the Public at 2 p.m.

PURPOSE: Annual Public Hearing to afford an opportunity for any person 
to present views regarding the activities of the Corporation.

PROCEDURES: Individuals wishing to address the hearing orally must 
provide advance notice to OPIC's Corporate Secretary no later than 5 
p.m., Wednesday, March 10, 2010. The notice must include the 
individual's name, organization, address and telephone number, and a 
concise summary of the subject matter to be presented.
    Oral presentations may not exceed ten (10) minutes. The time for 
individual presentations may be reduced proportionately, if necessary, 
to afford all participants who have submitted a timely request to speak 
an opportunity to be heard.
    Participants wishing to submit a written statement for the record 
must submit a copy of such statement to OPIC's Corporate Secretary no 
later than 5 p.m., Wednesday, March 10, 2010. Such statements must be 
typewritten, double-spaced and may not exceed twenty-five (25) pages.
    Upon receipt of the required notice, OPIC will prepare an agenda 
for the hearing identifying speakers, setting forth the subject on 
which each participant will speak, and the time allotted for each 
presentation. The agenda will be available at the hearing.
    A written summary of the hearing will be compiled, and will be made

[[Page 9005]]

available, upon written request, to OPIC's Corporate Secretary, at the 
cost of reproduction.

Contact Person for Information: Information on the hearing may be 
obtained from Connie M. Downs at (202) 336-8438, via e-mail at 
<a href="/cdn-cgi/l/email-protection#fc9f9392929599d298938b928fbc938c959fd29b938a"><span class="__cf_email__" data-cfemail="72111d1c1c1b175c161d051c01321d021b115c151d04">[email protected]</span></a>, or via facsimile at (202) 408-0136.

SUPPLEMENTARY INFORMATION: OPIC is a U.S. Government agency that 
provides, on a commercial basis, political risk insurance and financing 
in friendly developing countries and emerging democracies for 
environmentally sound projects that confer positive developmental 
benefits upon the project country while creating employment in the U.S. 
OPIC is required by section 231A(c) of the Foreign Assistance Act of 
1961, as amended (the ``Act'') to hold at least one public hearing each 
year.

    Dated: February 24, 2010.
Connie M. Downs,
OPIC Corporate Secretary.
[FR Doc. 2010-4105 Filed 2-24-10; 11:15 am]
BILLING CODE 3210-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
§ 573.530 Hydrogenated corn syrup. ( a ) *Identity.* The product is produced by hydrogenation of corn syrup over a nickel catalyst.
( b ) *Specifications.* The product contains 70 percent hydrogenated corn syrup and a maximum of 0.5 percent reducing sugars.
( c ) *Uses.* The product is used as a humectant and plasticizer in preparation of soft-moist dog and cat foods.
( d ) *Limitations.* The product is preferably stored in a closed, stainless steel or aluminum container. The level of use of the product shall not exceed 15 percent of the total weight of the pet food formulation.
( e ) *Labeling.* The labeling shall bear, in addition to other information required by the Act: ( 1 ) The name of the additive.
( 2 ) Adequate directions for use in accordance with the provisions in paragraph (d) of this section.
[45 FR 22920, Apr. 4, 1980]
June 25, 2015 

Mr. Dirk Carus 

2835 W College Ave 

Appleton, WI 54915 

Dear Mr. Carus: 

This letter is to inform you that we are unable to process your request for an exemption from 

Title 14, Code of Federal Regulations (14 CFR). It explains why we can not process your 

request and what you should do in the next 30 days. 

Why We Can Not Process Your Request 

We entered your June 22, exemption request into the public docket (No. FAA-2015-2415), 

but we are unable to process your request any further. The information you sent does not 

comply with the requirements of § 11.81 (copy enclosed). For us to consider the request any 

further, you must send us all of the following: 

 The specific section or sections of 14 CFR from which you seek relief, the extent of the 

relief you seek, and the reason you seek relief. 

 The reasons why granting the request would be in the public interest; that is, how it would 

benefit the public as a whole. 

 The reasons why the exemption would not adversely affect safety or how the exemption 

would provide a level of safety at least equal to that provided by the rule from which you 

seek an exemption. 

 Any additional information, views, or arguments available to support your request. 
2 

What You Should Do 

If you want us to process your request any further, you must send the information described 

earlier to reach us within 30 days. Please note that § 11.63(d) requires you to send your 

petition for exemption at least 120 days before the proposed effective date of the exemption. 

If We Do Not Hear From You 

If we do not hear from you within 30 days, we will close the docket without notifying you 

further. If you have any questions or require additional time, you may call (202) 267-9677. 

Sincerely, 

/s/ 

Brenda Robeson 

Program Analyst, Airmen and 

 Airspace Rules Division

Enclosure
Michigan Supreme Court

Lansing, Michigan

Bridget M. McCormack, Chief Justice

David F. Viviano,

Chief Justice Pro Tem

Stephen J. Markman

Brian K. Zahra

Richard H. Bernstein

Elizabeth T. Clement

Megan K. Cavanagh,

Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

 December 23, 2019

b1216

Order 

Clerk

December 23, 2019

157893

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellee,

v SC: 157893

COA: 342611 

Ottawa CC: 16-040422-FH

ROBERTO ALBERTO ALCALA,

Defendant-Appellant. 

_________________________________________/

By order of December 4, 2018, the application for leave to appeal the April 9, 

2018 order of the Court of Appeals was held in abeyance pending the decision in People 

v Dixon-Bey (Docket No. 156746). On order of the Court, leave to appeal having been 

denied in Dixon-Bey on July 29, 2019, 504 Mich ___ (2019), the application is again 

considered, and it is DENIED, because we are not persuaded that the question presented 

should be reviewed by this Court.
Exhibit








Aflac Incorporated 1st Quarter 2017 10-Q
EXHIBIT 10.9


Exhibit A


SECOND AMENDMENT TO THE
AFLAC INCORPORATED EXECUTIVE DEFERRED COMPENSATION PLAN
(As amended and restated effective September 1, 2015)
THIS AMENDMENT to the Aflac Incorporated Executive Deferred Compensation Plan (the “Plan”) is effective as stated below.
WITNESSETH:
WHEREAS, Aflac Incorporated (the “Company”) has previously established the Plan for the benefit of its eligible employees and their beneficiaries; and
WHEREAS, pursuant to Section 10.1 of the Plan, the Administrative Committee of the Plan (the “Committee”) is authorized to amend the Plan; and
WHEREAS, the Committee wishes to amend the Plan to provide that the Committee may approve new participating companies under the Plan.
NOW, THEREFORE, the Plan is hereby amended as follows, effective as of the date of approval of this Amendment:
		
	1.
	Section 1.36 is amended by deleting said section in its entirety and substituting in lieu thereof the following:




1.36    Participating Company means, as of the Effective Date, each of (i) the Controlling Company, and (ii) each of its Affiliates that are designated by the Controlling Company on Exhibit A hereto as Participating Companies herein.  In addition, any other Affiliate in the future may adopt the Plan with the consent of the Compensation Committee or the Administrative Committee, and such Affiliate’s name will be added to Exhibit A without the necessity of amending the Plan.
		
	2.
	Except as specifically amended hereby, the Plan will remain in full form and effect.